CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionReturn on equity is -471.2%, lower than 95% of its Biotechnology peers (median -22.3%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
703.68MUSDvs all stocks (USD)
Revenue (TTM)
87.53MUSDvs all stocks (USD)
Profit Margin
-231.59%vs Biotechnology peers
Beta
0.3210xvs all stocks
52-Week Change
-10.07%vs all stocks
Market Capitalization
703.68MUSDvs all stocks (USD)
Enterprise Value
648.94MUSDvs all stocks (USD)
Forward P/E
-10.07xvs Biotechnology peers
Price to Sales (TTM)
7.81xvs Biotechnology peers
Price to Book (MRQ)
13.68xvs Biotechnology peers
Enterprise to Revenue
7.41xvs Biotechnology peers
Enterprise to EBITDA
-4.09xvs Biotechnology peers
Gross Margin
89.92%vs Biotechnology peers
Profit Margin
-231.59%vs Biotechnology peers
Operating Margin
-81.62%vs Biotechnology peers
Return on Assets (TTM)
-49.59%vs Biotechnology peers
Return on Equity (TTM)
-471.16%vs Biotechnology peers
Revenue (TTM)
87.53MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.9850USDUpdated Sep 28, 2026Quarterly Revenue Growth
1775.40%vs Biotechnology peers
Gross Profit (TTM)
76.71MUSDvs all stocks (USD)
EBITDA (TTM)
-158.65MUSDvs all stocks (USD)
Net Income (TTM)
-202.70MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1775.43%vs Biotechnology peers
Operating Cash Flow (TTM)
-162.20MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-103.43MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
30.91MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
5.30MUSDFY2025 · Dec 31, 2025Gross Profit
25.62MUSDFY2025 · Dec 31, 2025Operating Income
-170.13MUSDvs all stocks (USD)
Pre-tax Income
-209.47MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-209.47MUSDFY2025 · Dec 31, 2025EBIT
-208.33MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-178.29MUSDFY2025 · Dec 31, 2025Research & Development
114.60MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
81.15MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.07MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.14MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-209.47MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-195.06MUSDFY2025 · Dec 31, 2025Free Cash Flow
-195.06MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
205.23MUSDFY2025 · Dec 31, 2025Income Tax Paid
185.00KUSDFY2025 · Dec 31, 2025Interest Paid
6.36MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-209.47MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
728.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
9.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
6.51MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-8.81MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
8.42MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.83MUSDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Net Intangibles (CF)
-9.62MUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
0.00USDFY2025 · Dec 31, 2025Long-term Debt Issuance
75.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-42.58MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
229.40MUSDFY2025 · Dec 31, 2025Shares Outstanding
90.48MSharesUpdated Sep 28, 2026Float Shares
70.57MSharesUpdated Sep 28, 2026Shares Short
18.03MSharesUpdated Sep 28, 2026Short Ratio
8.13daysvs all stocks
Short % of Shares Outstanding
20.02%vs all stocks
% Held by Insiders
1.02%vs all stocks
% Held by Institutions
110.91%vs all stocks
Total Cash (MRQ)
136.35MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.51USDUpdated Sep 28, 2026Total Debt (MRQ)
84.33MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.69xvs Biotechnology peers
Current Ratio (MRQ)
2.25xvs Biotechnology peers
Book Value per Share (MRQ)
0.5520USDUpdated Sep 28, 2026Total Assets
246.44MUSDvs all stocks (USD)
Total Current Assets
223.41MUSDFY2025 · Dec 31, 2025Total Liabilities
189.25MUSDFY2025 · Dec 31, 2025Total Non-current Assets
23.03MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
116.98MUSDFY2025 · Dec 31, 2025Total Current Liabilities
72.27MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
204.99MUSDFY2025 · Dec 31, 2025Other Short-term Investments
8.81MUSDFY2025 · Dec 31, 2025Inventory
1.83MUSDFY2025 · Dec 31, 2025Accounts Payable
12.45MUSDFY2025 · Dec 31, 2025Short-term Debt
5.84MUSDFY2025 · Dec 31, 2025Long-term Debt
81.33MUSDFY2025 · Dec 31, 2025Common Stock (Book)
8.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.16BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
57.20MUSDvs all stocks (USD)
52-Week Low
3.43USDUpdated Sep 28, 202652-Week High
10.82USDUpdated Sep 28, 202652-Week Change
-10.07%vs all stocks
Beta
0.3210xvs all stocks
50-Day MA
6.98USDUpdated Sep 28, 2026200-Day MA
6.08USDUpdated Sep 28, 2026Avg 10-Day Volume
2.12MSharesUpdated Sep 28, 2026Avg 30-Day Volume
2.17MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-2.44USDUpdated Sep 28, 2026Other Income / Expense
-42.27MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -471.2%, lower than 95% of its Biotechnology peers (median -22.3%)Significant
Return on equity: -4.71Industry median: -0.22Industry P5: -1.57Peers compared: 260
Debt-to-equity is 1.69×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 1.69Industry median: 0.07Industry P95: 0.93Peers compared: 260
Price-to-book is 13.68×, higher than 95% of its Biotechnology peers (median 2.86×)Significant
Price-to-book: 13.68Industry median: 2.86Industry P95: 13.08Peers compared: 260
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.90Profit Margin: -2.32
Significant cash reserves alongside high leverageNotable
Cash (USD): 136,352,992Total Debt (USD): 84,330,000Debt-to-Equity: 1.69
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Collegium Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Wecome Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Anglikang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ChemPartner Pharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Revenio Group Oyj
Tier 1ProductionApproval-Gated PipelineRule
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Konruns Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Lifotronic Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Annexon, Inc.
Tier 1ProductionApproval-Gated PipelineRule